Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3359-3365

  Pupilli, C ^a   Pinzani, P ^b   Salvianti, F ^b   Fibbi, B ^a   Rossi, M ^a   Petrone, L ^a   Perigli, G ^a   L De Feo, M ^a   Vezzosi, V ^a   Pazzagli, M ^b   Orlando, C ^b   Forti, G ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; BRAF GENE; CANCER DIAGNOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; DISEASE MARKER; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; CARCINOMA; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; THYROID TUMOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; ROC CURVE; THYROID NEOPLASMS;

EID: 84881514906     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1072     Document Type: Article

References (37)

1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
2. Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med. 2004;351:1764-1771.
3. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404.
4. Verburg FA, Mäder U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all otherDTCpatients. J Clin Endocrinol Metab. 2013;98:172-180.
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
6. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii.110-119.
7. Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest. 2012;35(6 suppl):40-44.
8. Gharib H, Papini E, Paschke R, et al; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract. 2010; 16(suppl 1):1-43.
9. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
10. Cantara S, Capezzone M, Marchisotta S, et al. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369.
11. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.NEngl J Med. 2012;367:705-715.
12. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
13. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762.
14. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559-4570.
15. Dalle Carbonare L, Frigo A, Francia G, et al. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. J Clin Endocrinol Metab. 2012; 97:E1249-E1256.
16. Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:2084-2092.
17. Milas M, Shin J, Gupta M, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg. 2010;252:643-651.
18. Urbanova M, Plzak J, Strnad H, Betka J. Circulating nucleic acids as a new diagnostic tool. Cell Mol Biol Lett. 2010;15:242-259.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
20. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8:83-95.
21. Vdovichenko KK, Markova SI, Belokhvostov AS. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci. 2004;1022:228-231.
22. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab. 2009;94:5001-5009.
23. Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.HeadNeck. 2010;32:229-234.
24. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9:435-441.
25. Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011;96:3615-3627.
26. British Thyroid Association, Royal College of Physicians. Diagnostic categories. Guidelines for the management of thyroid cancer. 2nd ed. Suffolk, UK: Lavenham Press; 2007:10.
27. Pinzani P, Salvianti F, Cascella R, et al. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta. 2010;411: 1319-1324.
28. Everitt BS. The Cambridge Dictionary of Statistics. 2nd ed. Cambridge, UK: Cambridge University Press; 2002.
29. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
30. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
31. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta. 2010;411:1611-1624.
32. Kwak JY, Jeong JJ, Kang SW, et al. Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas [published online ahead of print November 17, 2012]. Head Neck. doi:10.1002/hed.23195.
33. Yancovitz M, Yoon J, Mikhail M, et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn. 2007;9:178-183.
34. Xing J, Liu R, Xing M, Trink B. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun. 2011;404: 958-962.
35. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 2010;107:10649-10654.
36. Nucera C, Nehs MA, Nagarkatti SS, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16:296-309.
37. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011;42:500-506.